Eli & Co Lilly Ventures Fun... Net Worth

The estimated Net Worth of Eli & Co Lilly Ventures Fun... is at least $4.05 millió dollars as of 12 November 2014. Eli Fun owns over 164,963 units of Coherus Biosciences Inc stock worth over $4,045,885 and over the last 10 years Eli sold CHRS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Eli Fun CHRS stock SEC Form 4 insiders trading

Eli has made over 1 trades of the Coherus Biosciences Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Eli bought 164,963 units of CHRS stock worth $2,227,001 on 12 November 2014.

The largest trade Eli's ever made was buying 164,963 units of Coherus Biosciences Inc stock on 12 November 2014 worth over $2,227,001. On average, Eli trades about 164,963 units every 0 days since 2014. As of 12 November 2014 Eli still owns at least 3,042,019 units of Coherus Biosciences Inc stock.

You can see the complete history of Eli Fun stock trades at the bottom of the page.

Insiders trading at Coherus Biosciences Inc

Over the last 10 years, insiders at Coherus Biosciences Inc have traded over $94,360,509 worth of Coherus Biosciences Inc stock and bought 594,589 units worth $8,026,656 . The most active insiders traders include Llc Fmr, August J. Troendle és James Healy. On average, Coherus Biosciences Inc executives and independent directors trade stock every 26 days with the average trade being worth of $64,928. The most recent stock trade was executed by Mats Wahlstrom on 1 February 2024, trading 59,988 units of CHRS stock currently worth $100,180.

What does Coherus Biosciences Inc do?

coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp

Complete history of Eli Fun stock trades at Coherus Biosciences Inc

Coherus Biosciences Inc executives and stock owners

Coherus Biosciences Inc executives and other stock owners filed with the SEC include:

• Dennis Lanfear,
  Chairman of the Board, President, Chief Executive Officer
• Jean-Frederic Viret,
  Chief Financial Officer
• Dennis M. Lanfear,
  Chairman, Pres & CEO
• Vincent Anicetti,
  Chief Operating Officer
• Vladimir Vexler,
  Chief Scientific Officer
• Vladimir Vexler,
  Chief Scientific Officer
• Mats Wahlstrom,
  Lead Independent Director
• V. Bryan Lawlis,
  Independent Director
• Mary Szela,
  Independent Director
• Ali Satvat,
  Independent Director
• James Healy,
  Independent Director
• Samuel Nussbaum,
  Independent Director
• Kimberly Tzoumakas,
  Director
• Thomas Fitzpatrick,
  Chief Legal Officer
• Dr. Barbara K. Finck M.D.,
  Acting Chief Medical Officer
• Richard L. Hameister,
  Chief Quality Officer
• Michael Chen,
  Sr. VP of Commercial Analytics & Trade
• Michael A. Fleming,
  Chief Strategy Officer
• Rebecca Sunshine,
  Exec. VP of HR
• Chris Thompson,
  Exec. VP of Sales
• McDavid Stilwell,
  Chief Financial Officer
• Alan C. Herman,
  Chief Scientific Officer
• August J. Troendle,
  Director
• Christos Richards,
  Director
• Peter K. Watler,
  Chief Technical Officer
• Barbara K Finck,
  Chief Medical Officer
• Rita A Karachun,
  
• Llc Fmr,
  10% owner
• Biosimilar L.P.Kkr Biosimil...,
  
• Eli & Co Lilly Ventures Fun...,
  
• Sankyo Company, Ltd Daiichi,
  
• Georgia Erbez,
  
• Alan C Mendelson,
  Director
• Lee Nisley Newcomer,
  
• Mark Stolper,
  
• Charles W. Newton,
  
• Jill O'donnell Tormey,
  
• Michael Lee Ryan,
  
• Paul Reider,
  Chief Commercial Officer
• Mc David Stilwell,
  Chief Financial Officer
• Bryan J Mc Michael,
  Chief Financial Officer